--- title: "ProMIS Neurosciences (PMN) news: reverse split and offering" url: "https://aibio.space/companies/promis-neurosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PMN reverse split and offering news: ProMIS Neurosciences gets second 180-day period to meet Nasdaq bid price rule. ProMIS Neurosciences Inc." --- PMN ProMIS Neurosciences Inc. NASDAQ · Canada # ProMIS Neurosciences (PMN) news PMN reverse split and offering news Financings · 2025-08-13 ## [ProMIS Neurosciences files $50,000,000 shelf and up to $17,988,524 share sales plan](https://aibio.space/news/promis-neurosciences-files-50-000-000-shelf-up-17-988-524-share-sales/) ProMIS filed a $50,000,000 base shelf on Form S-3 and an at-the-market agreement with H.C. Wainwright & Co. for up to $17,988,524 of common shares, at a commission of up to 3.0%. The stock closed at $0.628 on August 11, 2025, and the supplement does not explain its float figures. ## Latest ProMIS Neurosciences news 1. 2025-07-07 Listings [ProMIS Neurosciences gets second 180-day period to meet Nasdaq bid price rule](https://aibio.space/news/promis-neurosciences-gets-second-180-day-period-meet-nasdaq-bid-price/) ProMIS now has until December 29, 2025 to lift its share price to at least $1.00. It said it may effect a reverse stock split if necessary. ## ProMIS Neurosciences at a glance - **Ticker**: PMN - **Listing**: NASDAQ - **Country**: Canada - **Cash, Jun 30, 2026**: $53.5 million ### Related companies - [DiagnaMed Holdings](https://aibio.space/companies/diagnamed/) CSE: DMED - [Hemostemix](https://aibio.space/companies/hemostemix/) TSXV: HEM - [Avicanna](https://aibio.space/companies/avicanna/) TSX: AVCN - [Quantum Biopharma](https://aibio.space/companies/quantum-biopharma/) NASDAQ: QNTM - [Medicenna Therapeutics](https://aibio.space/companies/medicenna-therapeutics/) TSX: MDNA - [Eupraxia Pharmaceuticals](https://aibio.space/companies/eupraxia-pharmaceuticals/) TSX: EPRX - [AbCellera Biologics](https://aibio.space/companies/abcellera-biologics/) NASDAQ: ABCL - [Rapid Dose Therapeutics](https://aibio.space/companies/rapid-dose-therapeutics/) CSE: DOSE ### Also on NASDAQ - [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) COYA - [Korro Bio](https://aibio.space/companies/korro-bio/) KRRO - [Black Hawk Acquisition](https://aibio.space/companies/black-hawk-acquisition/) BKHA - [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) VIR - [BioMarin Pharmaceutical](https://aibio.space/companies/biomarin-pharmaceutical/) BMRN - [Gossamer Bio](https://aibio.space/companies/gossamer-bio/) GOSS ## What ProMIS Neurosciences does ProMIS Neurosciences has in-licensed a patented technology platform to develop antibody therapies, therapeutic vaccines and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases. The EpiSelect platform uses computational modeling to identify conformational epitopes that are exposed on toxic, misfolded forms of a protein but not on the properly folded form. Antibodies raised against these epitopes are designed to target the disease-causing form without interfering with the healthy protein, and are humanized for potential use in patients. The text names Alzheimer's disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson's disease, progressive supranuclear palsy, corticobasal degeneration and schizophrenia as conditions the platform may address. The lead program, PMN310, is in the PRECISE-AD Phase 1b trial for Alzheimer's disease, with a blinded interim analysis anticipated in early third quarter 2026 and top-line data anticipated in early 2027. The pipeline chart lists programs in ALS, FTD, PD, DLB and HD, and the company says it is evaluating partnership and business development opportunities. | Product or program | What it is | Stage | |---|---|---| | PMN310 | Antibody for Alzheimer's disease, tested in the PRECISE-AD trial | Phase 1b | | EpiSelect platform | Computational platform identifying epitopes on misfolded proteins for antibody design | in-licensed platform technology | Summarised from the company's [10-K filed Mar 25, 2026](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/pmn-20251231x10k.htm). ## ProMIS Neurosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$33.4 million](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/) | [$10.6 million](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/) | | Net income (loss) | [-$39.7 million](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/) | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/) | | Cash from operations | [-$28.1 million](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/) | [-$27.2 million](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/) | | Cash and equivalents | [$6.1 million](https://www.sec.gov/Archives/edgar/data/1374339/000110465926095895/) | [$13.3 million](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/) | | Short-term investments | [$33,753](https://www.sec.gov/Archives/edgar/data/1374339/000110465926095895/) | [$33,051](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $53.4 million, plus short-term investments of $33,753, $53.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about ProMIS Neurosciences Did ProMIS Neurosciences do a reverse stock split? Our latest story on this, dated Jul 7, 2025: "ProMIS Neurosciences gets second 180-day period to meet Nasdaq bid price rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/promis-neurosciences-gets-second-180-day-period-meet-nasdaq-bid-price/). Has ProMIS Neurosciences raised money recently? Our latest story on this, dated Aug 13, 2025: "ProMIS Neurosciences files $50,000,000 shelf and up to $17,988,524 share sales plan". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/promis-neurosciences-files-50-000-000-shelf-up-17-988-524-share-sales/). What is the ticker symbol of ProMIS Neurosciences? ProMIS Neurosciences Inc. trades under the ticker PMN on NASDAQ. Where is ProMIS Neurosciences listed? ProMIS Neurosciences Inc. is listed on NASDAQ. Our directory also records these other listings: LSX:A41MFQ. What is the SEC CIK of ProMIS Neurosciences? The SEC Central Index Key (CIK) for ProMIS Neurosciences Inc. is 1374339. Its filings are on SEC EDGAR. How many shares does ProMIS Neurosciences have outstanding? 8,967,693 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is ProMIS Neurosciences listed under? Our directory records ProMIS Neurosciences Inc. under Canada. What does ProMIS Neurosciences do? Our directory classifies ProMIS Neurosciences Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of ProMIS Neurosciences? The ISIN recorded for ProMIS Neurosciences Inc. is CA74346M5054. Does aibio.space cover ProMIS Neurosciences? aibio.space lists ProMIS Neurosciences Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is ProMIS Neurosciences incorporated? SEC records list its state or country of incorporation as Z4. What does ProMIS Neurosciences develop? ProMIS Neurosciences has in-licensed a patented technology platform to develop antibody therapies, therapeutic vaccines and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases. The EpiSelect platform uses computational modeling to identify conformational epitopes that are exposed on toxic, misfolded forms of a protein but not on the properly folded form. What is PMN310 from ProMIS Neurosciences? PMN310: Antibody for Alzheimer's disease, tested in the PRECISE-AD trial Stage: Phase 1b. What is EpiSelect platform from ProMIS Neurosciences? EpiSelect platform: Computational platform identifying epitopes on misfolded proteins for antibody design Stage: in-licensed platform technology. Is ProMIS Neurosciences profitable? ProMIS Neurosciences Inc. reported a net loss of $39.7 million for the fiscal year ended Dec 31, 2025, and used $28.1 million of cash in operations, per its annual report to the SEC. ## Investor discussion: ProMIS Neurosciences Members talk about ProMIS Neurosciences (PMN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at ProMIS Neurosciences, newest first. Each line links the filing it comes from. 1. 2026-03-25 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034613/pmn-20260325xs3.htm) 2. 2026-01-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/pmn-20260129xex99d1.htm) 3. 2025-12-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1374339/000110465925121627/pmn-20251212x8k.htm) 4. 2025-11-24 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1374339/000110465925115182/pmn-20251124xex99d1.htm) 5. 2025-10-03 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1374339/000110465925096657/pmn-20251117xdef14a.htm) 6. 2025-09-23 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1374339/000110465925092569/pmn-20251117xpre14a.htm) 7. 2025-08-13 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1374339/000155837025011396/pmn-20250812xs3.htm) 8. 2025-07-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1374339/000155837025009352/pmn-20250721x8k.htm) 9. 2025-07-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1374339/000155837025009112/pmn-20250703x8k.htm) 10. 2025-03-31 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1374339/000155837025004073/pmn-20250331x424b5.htm) 11. 2025-01-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1374339/000155837025000075/pmn-20250103x8k.htm) 12. 2024-11-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1374339/000155837024015634/pmn-20240930x10q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PMN on TradingView](https://www.tradingview.com/symbols/NASDAQ-PMN/). ## SEC filings and registration - **SEC name**: ProMIS Neurosciences Inc. - **CIK**: 1374339 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: PMN (Nasdaq) - **State or country of incorporation**: Z4 - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: SUITE 200, 1920 YONGE STREET, TORONTO, Ontario, Canada, M4S 3E2 - **Phone**: 416-847-6898 - **Shares outstanding**: 8,967,693 as of 2026-08-13 (10-Q filed 2026-08-13) - **Former names**: AMORFIX LIFE SCIENCES LTD ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813x8k.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1374339/000110465926095895/pmn-20260630x10q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/pmn-20260728x8k.htm) filed 2026-07-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1374339/000110465926064545/pmn-20260520x8k.htm) filed 2026-05-20 - [10-Q](https://www.sec.gov/Archives/edgar/data/1374339/000110465926059035/pmn-20260331x10q.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512x8k.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1374339/000110465926041483/pmn-20260520xdef14a.htm) filed 2026-04-09 - [S-3](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034613/pmn-20260325xs3.htm) filed 2026-03-25 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001374339), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details ProMIS Neurosciences Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PMN, recorded under Canada. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: ProMIS Neurosciences Inc. - **Ticker**: PMN - **Listing**: NASDAQ - **Country or territory**: Canada - **Business scope**: Biotechnology - **ISIN**: CA74346M5054 - **Other listed symbols**: LSX:A41MFQ - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PMN/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/promis-neurosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "ProMIS Neurosciences (PMN) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/promis-neurosciences/